Loading...
Loading...
CELU| Name | Value |
|---|---|
| Revenues | 14.7M |
| Cost of Revenue | 1.6M |
| Gross Profit | 13.0M |
| Operating Expense | 20.4M |
| Operating I/L | -7.4M |
| Other Income/Expense | -14.6M |
| Interest Income | 0.1M |
| Pretax | -22.0M |
| Income Tax Expense | -13.5M |
| Net Income/Loss | -22.0M |
Celularity Inc. is a clinical-stage biotechnology company specializing in the development of off-the-shelf placental-derived allogeneic cell therapies for cancer, immune, and infectious diseases. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its revenue streams come from the sale and licensing of products used in surgical and wound care markets, such as Biovance and Interfyl, as well as the collection and storage of stem cells from umbilical cords and placentas under the LifebankUSA brand.
